Nachrichten zur Biora Therapeutics Aktie

Citizens reiterates Bicara Therapeutics stock rating on trial progress…

This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.…

This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.…

Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price objective, citing the…

CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers,…

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company…

Sonnet BioTherapeutics completes $2 million convertible note and warrant sale…

…

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic…

…

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to…

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic…

…

Bicara Therapeutics is working with Morgan Stanley on a US initial public offering, people familiar with the situation said, as…

Earnings call: Biora Therapeutics reports progress on NaviCap and BioJet platforms…

…

…